{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03692429",
            "orgStudyIdInfo": {
                "id": "CYAD-N2L-101"
            },
            "organization": {
                "fullName": "Celyad Oncology SA",
                "class": "INDUSTRY"
            },
            "briefTitle": "alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells",
            "officialTitle": "An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer",
            "acronym": "alloSHRINK",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "alloshrink-standard-chemotherapy-regimen-and-immunotherapy-with-allogeneic-based-cyad-chimeric-antigen-receptor-t-cells"
        },
        "statusModule": {
            "statusVerifiedDate": "2020-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-11-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2021-11-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2036-02-17",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-08-31",
            "studyFirstSubmitQcDate": "2018-10-01",
            "studyFirstPostDateStruct": {
                "date": "2018-10-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2020-11-19",
            "lastUpdatePostDateStruct": {
                "date": "2020-11-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celyad Oncology SA",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy",
            "detailedDescription": "This Study aims to determine and confirm the recommended dose of the allogeneic CYAD-101 cells after standard FOLFOX or FOLFIRI chemotherapy in patients with unresectable metastatic colorectal cancer"
        },
        "conditionsModule": {
            "conditions": [
                "Unresectable Metastatic Colorectal Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 49,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CYAD-101 with FOLFOX",
                    "type": "EXPERIMENTAL",
                    "description": "Infusion after standard FOLFOX chemotherapy",
                    "interventionNames": [
                        "Drug: CYAD-101",
                        "Drug: FOLFOX"
                    ]
                },
                {
                    "label": "CYAD-101 with FOLFIRI",
                    "type": "EXPERIMENTAL",
                    "description": "Infusion after standard FOLFIRI chemotherapy",
                    "interventionNames": [
                        "Drug: CYAD-101",
                        "Drug: FOLFIRI"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CYAD-101",
                    "description": "Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells",
                    "armGroupLabels": [
                        "CYAD-101 with FOLFIRI",
                        "CYAD-101 with FOLFOX"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "FOLFOX",
                    "description": "5-FU, leucovorin and oxaliplatin",
                    "armGroupLabels": [
                        "CYAD-101 with FOLFOX"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "FOLFIRI",
                    "description": "5-FU, leucovorin and irinotecan",
                    "armGroupLabels": [
                        "CYAD-101 with FOLFIRI"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurence of Dose Limiting Toxicities",
                    "timeFrame": "Up to 82 days post first CYAD-101 Infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically proven metastatic adenocarcinoma of the colon or rectum.\n\n   1. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.\n   2. Recurrent/progressing disease after at least one line of systemic therapy for metastatic disease.\n   3. Unequivocal and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).\n   4. FOLFOX segment: Neurotoxicity less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 from previous chemotherapy.\n   5. FOLFIRI segment: Documented progressive disease (PD) under FOLFIRI treatment, with or without targeted therapy, given within 3 months prior to study registration. Anti-cancer therapy post FOLFIRI-documented PD prior to study registration is authorized if discontinued at least 7 days before the planned study registration. Radiotherapy is not authorized.\n2. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n3. The patient must have adequate bone marrow reserve, hepatic, renal, pulmonary and cardiac functions.\n\nExclusion Criteria:\n\n1. The patient has a confirmed or history of tumor involvement in the central nervous system (CNS).\n2. Any non-cancer-directed investigational agent within 3 weeks before the planned day for the first CYAD-101 administration.\n3. Filgrastim (Granulocyte-Colony-Stimulating Factor \\[G-CSF\\]) or similar growth factors within 7 days before the planned day for the first CYAD-101 administration.\n4. Prior allogeneic stem cell transplantation, chimeric antigen receptor therapy or other genetically modified T-cell therapy.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Celyad Oncology Medical Monitor, MD, PhD",
                    "role": "CONTACT",
                    "phone": "+3210394100",
                    "email": "clinicaltrials@celyad.com"
                }
            ],
            "locations": [
                {
                    "facility": "Moffit Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kim Dae Won, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Kim Dae Won",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Institut Jules Bordet",
                    "status": "RECRUITING",
                    "city": "Brussels",
                    "zip": "1000",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Michel Dubuisson",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Alain Hendlisz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.85045,
                        "lon": 4.34878
                    }
                },
                {
                    "facility": "UZ Antwerpen",
                    "status": "RECRUITING",
                    "city": "Edegem",
                    "zip": "2650",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Hans Prenen, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Hans Prenen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.15662,
                        "lon": 4.44504
                    }
                },
                {
                    "facility": "UZ Leuven",
                    "status": "RECRUITING",
                    "city": "Leuven",
                    "zip": "3000",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Hilde Mars\u00e9",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Eric Van Cutsem, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35191428",
                    "type": "DERIVED",
                    "citation": "Michaux A, Mauen S, Breman E, Dheur MS, Twyffels L, Saerens L, Jacques-Hespel C, Gauthy E, Agaugue S, Gilham DE, Sotiropoulou PA. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy. J Immunother. 2022 Apr 1;45(3):150-161. doi: 10.1097/CJI.0000000000000413."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "annotationSection": {
        "annotationModule": {
            "unpostedAnnotation": {
                "unpostedResponsibleParty": "Celyad Oncology SA",
                "unpostedEvents": [
                    {
                        "type": "RELEASE",
                        "date": "2022-10-26"
                    },
                    {
                        "type": "RESET",
                        "date": "2023-09-05"
                    }
                ]
            }
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "United Kingdom"
            ],
            "submissionTracking": {
                "estimatedResultsFirstSubmitDate": "2022-10-26",
                "submissionInfos": [
                    {
                        "releaseDate": "2022-10-26",
                        "resetDate": "2023-09-05"
                    }
                ]
            }
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                }
            ]
        }
    },
    "hasResults": false
}